Xenon Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
Le PDG Xenon Pharmaceuticals est Ian Mortimer, nommé en Mar2018, a un mandat de 6.67 ans. La rémunération annuelle totale est $ 10.12M, composée du salaire de 6.6% et des bonus 93.4%, y compris les actions et options de la société. détient directement 0.06% des actions de la société, d'une valeur de $ 1.80M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.3 ans et 3.7 ans.
Informations clés
Ian Mortimer
Directeur général
US$10.1m
Rémunération totale
| Pourcentage du salaire du PDG | 6.6% |
| Durée du mandat du directeur général | 6.7yrs |
| Propriété du PDG | 0.06% |
| Durée moyenne d'occupation des postes de direction | 4.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 3.7yrs |
Mises à jour récentes de la gestion
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29
Recent updates
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 20Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?
Aug 09Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$213m |
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$189m |
| Dec 31 2023 | US$10m | US$666k | -US$182m |
| Sep 30 2023 | n/a | n/a | -US$176m |
| Jun 30 2023 | n/a | n/a | -US$165m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$9m | US$595k | -US$126m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$91m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$4m | US$524k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$59m |
| Mar 31 2021 | n/a | n/a | -US$37m |
| Dec 31 2020 | US$2m | US$462k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$2m | US$421k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$42m |
| Dec 31 2018 | US$923k | US$342k | -US$34m |
| Sep 30 2018 | n/a | n/a | -US$34m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$945k | US$312k | -US$31m |
Rémunération vs marché: La rémunération totale de Ian ($USD 10.12M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 6.57M ).
Rémunération et revenus: La rémunération de Ian a augmenté alors que l'entreprise n'est pas rentable.
PDG
Ian Mortimer (48 yo)
6.7yrs
Titularisation
US$10,117,829
Compensation
Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been an Independent Director at Perimeter Medical Imag...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 6.7yrs | US$10.12m | 0.060% $ 1.8m | |
| Chief Financial Officer | 3.4yrs | US$3.52m | 0% $ 0 | |
| Executive Vice President of Strategy & Innovation | no data | US$2.37m | pas de données | |
| Chief Commercial Officer | 4.3yrs | US$2.76m | 0.0053% $ 158.4k | |
| Chief Medical Officer | 3.3yrs | US$3.58m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 2yrs | US$3.55m | pas de données | |
| Executive Vice President of Human Resources | 5.2yrs | pas de données | pas de données | |
| Executive Vice President of Drug Discovery | 8.8yrs | US$545.00k | pas de données | |
| Executive Vice President of R&D Operations | 4.3yrs | pas de données | pas de données |
4.3yrs
Durée moyenne de l'emploi
54.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de XENE est considérée comme expérimentée (ancienneté moyenne 4.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 3.4yrs | US$10.12m | 0.060% $ 1.8m | |
| Independent Director | 1.3yrs | US$770.91k | pas de données | |
| Independent Director | 20.8yrs | US$560.09k | 0.038% $ 1.1m | |
| Independent Director | 4yrs | US$559.58k | pas de données | |
| Independent Director | 9.5yrs | US$561.42k | 0.0026% $ 79.2k | |
| Independent Chairman | 8.2yrs | US$588.37k | 0.033% $ 989.2k | |
| Independent Director | 1.3yrs | US$770.91k | pas de données | |
| Independent Director | 3.4yrs | US$548.57k | pas de données |
3.7yrs
Durée moyenne de l'emploi
61.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de XENE sont considérés comme expérimentés (ancienneté moyenne 3.7 ans).